Recent Quotes
My Watchlist
Indicators
Markets
Stocks
Funds
Tools
Overview
News
Currencies
International
Treasuries

Alnylam Pharmaceuticals (NQ: ALNY )

172.85 USD +0.47 (+0.27%)
Streaming Delayed Price Updated: 4:10 AM EST, Jan 25, 2021 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 200
Open 172.38
Bid (Size) 169.05 (1)
Ask (Size) 176.14 (1)
Prev. Close 172.38
Today's Range 172.38 - 172.85
52wk Range 84.97 - 175.41
Shares Outstanding 100,522,411
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year

Top News

More News
Alnylam Launches “Alnylam P5x25” Strategy for Planned Transition to a Top Five Biotech in Market Capitalization Over Next Five Years
Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, today announced its new 5-year strategy “Alnylam P5x25” focused on the Company’s planned transition to a top-5... 
From Business Wire News Releases
Alnylam Reports Positive Topline Results from HELIOS-A Phase 3 Study of Vutrisiran in Patients with hATTR Amyloidosis with Polyneuropathy
Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, announced today that the HELIOS-A Phase 3 study of vutrisiran, an investigational RNAi therapeutic in development... 
From Business Wire News Releases

Performance

YTD
+34.93%
+34.93%
1 Month
+28.92%
+28.92%
3 Month
+34.34%
+34.34%
6 Month
+9.74%
+9.74%
1 Year
+47.70%
+47.70%

More News

Read More
Alnylam to Webcast Presentation at 39th Annual J.P. Morgan Healthcare Conference
From Business Wire News Releases
Alnylam Appoints Tolga Tanguler Chief Commercial Officer and Also Announces New CEMEA, Medical Affairs, and Compliance Leaders
From Business Wire News Releases
Alnylam Announces 2021 Product and Pipeline Goals and Provides Program Updates at R&D Day
From Business Wire News Releases
Alnylam to Webcast Virtual R&D Day
From Business Wire News Releases
CENTOGENE and Alnylam Pharmaceuticals Launch a New Clinical Program Aimed at Revolutionizing the Diagnosis of Hereditary Transthyretin-Related Amyloidosis (“ATTRv”)
From GlobeNewswire News Releases
First Week of September 17th Options Trading For Alnylam Pharmaceuticals (ALNY)
Tags Stocks
From Market News Video
Alnylam Issues 2nd Annual Patient Access Philosophy Report Highlighting Broad Access to the Company’s Approved Therapies
From Business Wire News Releases
10 Health Care Stocks Showing Unusual Options Activity In Today's Session
Tags Benzinga PFE CORT
From Benzinga
3 Lesser-Known Biotech Stocks that are Surging
Tags Pharma/Biotech Stocks / Equities
From Blogs - TalkMarkets
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.